Does Zydus’ Promising CAPS Candidate Have An Edge Over Novartis’ Ilaris?
Potential In Chronic Inflammatory Diseases
Zydus has established proof of concept for ZYIL1, a NLRP3 inflammasome inhibitor to treat cryopyrin-associated periodic syndromes, via Phase II trials in Australia. Will the oral drug have an upper hand over injectables like Novartis’ Ilaris?
You may also be interested in...
The final Phase III readout for Ilaris (canakinumab) in NSCLC, this time in the adjuvant setting, missed the primary endpoint. One more lung cancer trial is under way, a Phase II neoadjuvant study.
Zydus Lifesciences is building a rare disease-focused pipeline as a differentiating strategy, managing director Sharvil Patel tells Scrip in an interview. Innovation and patient centricity at heart, digital initiatives are being implemented to transform the company into a ‘future ready’ healthcare organization
Evolving challenges will keep the COVID-19 pipeline active, while oncology, immunology and CNS are areas also expected to see much progress in 2022. Industry executives look forward to the year in therapeutic R&D.